BIOMARIN PHARMACEUTICAL INC Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2020-02-27
- BIOMARIN PHARMACEUTICAL INC other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2019-12-31 was $0.00.
- BIOMARIN PHARMACEUTICAL INC other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2019-09-30 was $0.00.
- BIOMARIN PHARMACEUTICAL INC other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2019-06-30 was $0.00.
- BIOMARIN PHARMACEUTICAL INC other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2019-03-31 was $0.00.
- BIOMARIN PHARMACEUTICAL INC other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2019 was $0.00.
- BIOMARIN PHARMACEUTICAL INC other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2018 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $0.00 10-K · filed 2020-02-27 |
| 2019-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2019-11-04 | $0.00 derived: sum of 2 quarters · filed 2019-11-04 | $0.00 10-Q/A · filed 2019-11-04 | $0.00 derived: sum of 4 quarters · filed 2019-11-04 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $0.00 10-Q · filed 2019-08-02 | $0.00 derived: sum of 3 quarters · filed 2019-08-02 | |
| 2019-03-31 | $0.00 10-Q · filed 2019-04-29 | $0.00 derived: sum of 2 quarters · filed 2019-04-29 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $0.00 10-K · filed 2019-02-28 | ||
| 2018-09-30 | $0.00 10-Q · filed 2018-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |